Jeffrey A Norton1, Teresa Kim2, Joseph Kim3, Martin D McCarter4, Kaitlyn J Kelly5, Joyce Wong6, Jason K Sicklick7. 1. Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA. 2. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Division of Surgical Oncology, Department of Surgery, State University of New York, Stony Brook, NY, USA. 4. Division of Surgical Oncology, Department of Surgery, University of Colorado, Aurora, CO, USA. 5. Division of Surgical Oncology, Moores UCSD Cancer Center, University of California San Diego, UC San Diego Health Sciences, 3855 Health Sciences Drive, Mail Code 0987, La Jolla, CA, 92093-0987, USA. 6. Department of Surgery, The Pennsylvania State University, College of Medicine, Hershey, PA, USA. 7. Division of Surgical Oncology, Moores UCSD Cancer Center, University of California San Diego, UC San Diego Health Sciences, 3855 Health Sciences Drive, Mail Code 0987, La Jolla, CA, 92093-0987, USA. jsicklick@ucsd.edu.
Abstract
INTRODUCTION: The current era of gastric surgery is marked by low morbidity and mortality rates, innovative strategies to approach resections with a minimally invasive fashion or hyperthermic intraperitoneal chemotherapy (HIPEC), as well as improved understanding of the biology of sporadic and hereditary stromal, neuroendocrine, and epithelial malignancies. METHODS: In 2017, the Society for Surgery of the Alimentary Tract convened a State-of-the-Art Conference on Current Surgical Management of Gastric Tumors with both international experts and emerging leaders in the field of gastric surgery. RESULTS: Martin D. McCarter, MD of the University of Colorado discussed the current management of gastric gastrointestinal stromal tumors (GIST). Kaitlyn J. Kelly, MD of the University of California, San Diego discussed the management of gastric carcinoid tumors. Jeffrey A. Norton of Stanford University discussed recent advances in the management of gastric adenocarcinoma including a focus on hereditary diffuse gastric cancer (HDGC). Joseph Kim, MD of Stony Brook University discussed a systematic approach to minimally invasive gastrectomy for cancer. Joyce Wong, MD of Pennsylvania State University discussed the role for cytoreductive surgery (CRS) and HIPEC for gastric adenocarcinoma. CONCLUSIONS: This review provides gastrointestinal surgeons with a concise update on the current surgical management of gastric tumors.
INTRODUCTION: The current era of gastric surgery is marked by low morbidity and mortality rates, innovative strategies to approach resections with a minimally invasive fashion or hyperthermic intraperitoneal chemotherapy (HIPEC), as well as improved understanding of the biology of sporadic and hereditary stromal, neuroendocrine, and epithelial malignancies. METHODS: In 2017, the Society for Surgery of the Alimentary Tract convened a State-of-the-Art Conference on Current Surgical Management of Gastric Tumors with both international experts and emerging leaders in the field of gastric surgery. RESULTS: Martin D. McCarter, MD of the University of Colorado discussed the current management of gastric gastrointestinal stromal tumors (GIST). Kaitlyn J. Kelly, MD of the University of California, San Diego discussed the management of gastric carcinoid tumors. Jeffrey A. Norton of Stanford University discussed recent advances in the management of gastric adenocarcinoma including a focus on hereditary diffuse gastric cancer (HDGC). Joseph Kim, MD of Stony Brook University discussed a systematic approach to minimally invasive gastrectomy for cancer. Joyce Wong, MD of Pennsylvania State University discussed the role for cytoreductive surgery (CRS) and HIPEC for gastric adenocarcinoma. CONCLUSIONS: This review provides gastrointestinal surgeons with a concise update on the current surgical management of gastric tumors.
Entities:
Keywords:
Gastric tumor; Management of gastric tumors; Surgery; Surgery morbidity; Surgery mortality; Surgical management
Authors: Linda Bardram; Thomas V O Hansen; Anne-Marie Gerdes; Susanne Timshel; Lennart Friis-Hansen; Birgitte Federspiel Journal: Fam Cancer Date: 2014-06 Impact factor: 2.375
Authors: Heikki Joensuu; Aki Vehtari; Jaakko Riihimäki; Toshirou Nishida; Sonja E Steigen; Peter Brabec; Lukas Plank; Bengt Nilsson; Claudia Cirilli; Chiara Braconi; Andrea Bordoni; Magnus K Magnusson; Zdenek Linke; Jozef Sufliarsky; Massimo Federico; Jon G Jonasson; Angelo Paolo Dei Tos; Piotr Rutkowski Journal: Lancet Oncol Date: 2011-12-06 Impact factor: 41.316
Authors: P C Hebbard; A Macmillan; D Huntsman; P Kaurah; F Carneiro; X Wen; A Kwan; D Boone; F Bursey; J Green; B Fernandez; D Fontaine; D A Wirtzfeld Journal: Ann Surg Oncol Date: 2009-05-01 Impact factor: 5.344
Authors: Suling J Lin; Johann A Gagnon-Bartsch; Iain Beehuat Tan; Sophie Earle; Louise Ruff; Katherine Pettinger; Bauke Ylstra; Nicole van Grieken; Sun Young Rha; Hyun Cheol Chung; Ju-Seog Lee; Jae Ho Cheong; Sung Hoon Noh; Toru Aoyama; Yohei Miyagi; Akira Tsuburaya; Takaki Yoshikawa; Jaffer A Ajani; Alex Boussioutas; Khay Guan Yeoh; Wei Peng Yong; Jimmy So; Jeeyun Lee; Won Ki Kang; Sung Kim; Yoichi Kameda; Tomio Arai; Axel Zur Hausen; Terence P Speed; Heike I Grabsch; Patrick Tan Journal: Gut Date: 2014-11-10 Impact factor: 23.059
Authors: Pushpa Neppala; Sudeep Banerjee; Paul T Fanta; Mayra Yerba; Kevin A Porras; Adam M Burgoyne; Jason K Sicklick Journal: Cancer Metastasis Rev Date: 2019-09 Impact factor: 9.264